<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03576651</url>
  </required_header>
  <id_info>
    <org_study_id>JHL-CLIN-1149-01</org_study_id>
    <nct_id>NCT03576651</nct_id>
  </id_info>
  <brief_title>A Study to Compare the Pharmacokinetics of JHL1149 and Bevacizumab (Avastin) in Healthy Male Volunteers</brief_title>
  <official_title>A Phase I, Double-blind, Randomized, Parallel-group, Single-dose, Three-Arm Study to Compare the Pharmacokinetics and to Evaluate the Tolerability, Safety and Immunogenicity of JHL1149 and Bevacizumab (Avastin) in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>JHL Biotech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>JHL Biotech, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I, Double-blind, Randomized, Parallel-group, Single-dose, Three-Arm Study to
      Compare the Pharmacokinetics and to Evaluate the Tolerability, Safety and Immunogenicity of
      JHL1149 and Bevacizumab (Avastin) Sourced from the European Union (EU) and the Union States
      (US) in Healthy Male Volunteers
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 24, 2018</start_date>
  <completion_date type="Actual">December 13, 2019</completion_date>
  <primary_completion_date type="Actual">September 17, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC0-inf</measure>
    <time_frame>up to 71 days</time_frame>
    <description>area under the concentration-time curve from time zero to infinity (AUC0-inf)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUClast</measure>
    <time_frame>up to 71 days</time_frame>
    <description>Area under the serum concentration-time curve from time 0 to last quantifiable concentration (AUClast).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>up to 71 days</time_frame>
    <description>Maximum serum concentration just prior to end of infusion (Cmax)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">154</enrollment>
  <condition>Healthy Male Subjects</condition>
  <arm_group>
    <arm_group_label>JHL1149</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>US-sourced-Avastin™</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>EU-sourced Avastin™</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>JHL1149</intervention_name>
    <description>Each patient may receive single dose of JHL1149 1mg/kg by intravenous infusion</description>
    <arm_group_label>JHL1149</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Each patient may receive single dose of Avastin 1mg/kg by intravenous infusion</description>
    <arm_group_label>US-sourced-Avastin™</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Each patient may receive single dose of Avastin 1mg/kg by intravenous infusion</description>
    <arm_group_label>EU-sourced Avastin™</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male volunteers,

          2. Age range of 21-55 years (inclusive).

          3. BMI range of 18.0-30.0 kg/m2 (inclusive) and a total body weight &gt;50 kg.

          4. Medically healthy subjects with normal organ functions and laboratory values

          5. Subjects must be willing to use adequate contraception and not donate sperm from
             admission to clinical research center until 6 months post dosing.

          6. All intermittent medications including over the counter, herbal and nutriceuticals,
             must be stopped at least 14 days prior to admission to the clinical research center.

          7. Ability and willingness to abstain from alcohol 48hrs prior to admission to the
             clinical research center, and throughout the dosing and evaluation period.

          8. No significant medical history per the PI judgment.

          9. ECGs (via 12 lead) showing normalized cumulative sum (NCS) findings per PI judgment

         10. Ability to provide informed consent for the study.

        Exclusion Criteria:

          1. Previous treatment with an anti-vascular endothelial growth factor (VEGF) antibody or
             any other antibody or protein targeting the VEGF receptor or treatment with an
             immunobiological drug during the last three months.

          2. Previous history of cancer other than adequately treated basal cell or squamous cell
             carcinoma of the skin.

          3. Received blood transfusions and blood donation within 3 months before screening date.

          4. Resting blood pressure is less than 90/40 mmHg or greater than 140/90 mmHg.

          5. Any other severe physical incapacity.

          6. Positive serological test for hepatitis B surface antigen or positive antibody for
             hepatitis C virus or positive antibody for human immunodeficiency virus (type 1 and
             2).

          7. Tuberculosis (TB) or an acute systemic infection; demonstrated by positive
             QuantiFERON-TB and/or Chest radiograph conducted up to 3 months prior or during the
             screening visit.

          8. Major surgery planned for the study duration or cases with major surgery in the past
             28 days before screening.

          9. History of relevant drug and/or food related allergies.

         10. History of or known hypersensitivity to bevacizumab or other recombinant human or
             humanized antibodies or inactive ingredients.

         11. History of alcohol and or drug abuse/addiction.

         12. Positive alcohol breath test and drug screen for opiates, methadone, cocaine,
             amphetamines, cannabinoids, barbiturates, benzodiazepines.

         13. Strenuous exercise 96 hrs prior to admission to the clinical research center.

         14. Any significant or acute illness within 30 days prior to the expected first dose of
             study drug.

         15. Unsuitable veins for infusion and/or venepuncture.

         16. History of bleeding disorders, thromboembolic conditions, gastrointestinal
             perforations or any fistulae, orthostatic hypotension, fainting spells, blackouts for
             any reasons; as well as presence of a non-healing wound or fracture.

         17. Participation in another clinical study where the investigational drug was received
             within &lt; 5 x half-lives of the drug (120 days prior to screening).

         18. Any condition or displayed behaviour that the investigator in their best clinical
             judgement believes could be detrimental the subject's participation in the study or
             result in unfavourable outcomes for the subject or study (eg. Clear signs that the
             patient is withholding information on their substance use/abuse status).
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>MHAT Lyulin EAD</name>
      <address>
        <city>Sofia</city>
        <zip>1336</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>June 25, 2018</study_first_submitted>
  <study_first_submitted_qc>June 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 3, 2018</study_first_posted>
  <last_update_submitted>January 5, 2020</last_update_submitted>
  <last_update_submitted_qc>January 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

